International Journal of Pharmaceutical Research and Applications
Volume 10, Issue 4 July-Aug 2025, pp: 466-481 www.ijprajournal.com ISSN: 2456-4494

To Study the Antioxidant and Anti-Inflammatory Potential of Achyranthes Aspera Linn in Cardiovascular Disorders

Sushant Tiwari, Prof. (Dr.) Dharmendra Ahuja*
Faculty of Pharmaceutical Sciences, Jayoti Vidyapeeth Women's University, Jaipur, 303122, India.
Dean & Professor, Faculty of Pharmaceutical Sciences, Jayoti Vidyapeeth Women's University, Jaipur, 303122, India.

Date of Submission: 20-07-2025 Date of Acceptance: 30-07-2025

ABSTRACT
A common therapeutic plant in traditional medical systems, Achyranthes aspera Linn. has attracted more scientific attention due to its many pharmacological characteristics, including its capacity to reduce inflammation and produce antioxidants. Chronic inflammation and oxidative stress are characteristics of CVDs, which remain the leading cause of morbidity and death globally. The bioactive phytoconstituents of A. asperaare thoroughly examined in this study along with their mechanistic functions in reducing oxidative damage and inflammatory cascades linked to the pathophysiology of CVD. Preclinical research, in vitro tests, and scant clinical knowledge point to potential cardioprotective benefits such NF-κB signaling modulation, pro-inflammatory cytokine suppression, and endogenous antioxidant enzyme increase. Additionally, the study emphasizes methodological constraints, research gaps, and future directions for standardizing phytochemical analysis and medicinal validation. In order to inspire aspiring researchers and medical students to conduct creative, evidence-based investigations in phytomedicine, this publication attempts to bridge the gap between ethnopharmacological knowledge and contemporary biomedical research. While encouraging a stronger dedication to translational research and scientific inquiry, an understanding of Achyranthes aspera's therapeutic potential in cardiovascular health may lead to new opportunities for plant-based therapies in the management of chronic diseases.

Keywords: Antioxidant, Anti-inflammatory, Cardioprotective, Ethnopharmacological, Phytomedicine, etc.

I. INTRODUCTION

In a recent study it was found that there were 612 million CVD cases in 2021, which accounted for 26.8% of all fatalities. The overall number of deaths from CVD has increased, primarily as a result of population expansion and aging, even though age-standardized mortality rates decreased by 34.3% between 1990 and 2021. Chronic inflammation and oxidative stress play a key role in the pathophysiology of CVDs. (Alagesboopathi, 2013) Atherosclerosis and other cardiovascular problems are exacerbated by endothelial dysfunction, lipid peroxidation, and vascular inflammation brought on by an excess of ROS. By encouraging the release of pro-inflammatory cytokines and adhesion molecules, chronic inflammation makes these problems even worse by boosting plaque development and instability. In the pathophysiology of CVDs, the interplay between oxidative stress and inflammation is essential. When reactive oxygen species (ROS) and antioxidant defenses are not balanced, oxidative stress takes place. This can lead to endothelial dysfunction, lipid peroxidation, and DNA damage. At the same time, persistent inflammation makes vascular damage worse by encouraging thrombosis and atherosclerosis. The necessity of treatment approaches that target both oxidative stress and inflammatory pathways is highlighted by these interconnected processes. (Bhattarai, 1992)

Using substances derived from plants for therapeutic purposes, or phytotherapy, has gained popularity as an additional strategy for controlling CVDs. Bioactive components with anti-inflammatory and antioxidant qualities, including terpenoids, alkaloids, flavonoids, and saponins, are abundant in medicinal plants. By modifying lipid profiles, preventing platelet aggregation, and enhancing endothelial function, these substances can reduce cardiovascular risk factors. (Bir & Sidhu, 1979) Particularly in areas with restricted access to synthetic medications, the incorporation of phytotherapy into traditional treatment plans provides a comprehensive approach to cardiovascular health.

The perennial herbaceous plant Achyranthes aspera Linn., also called "Prickly Chaff Flower," is a member of the Amaranthaceae

International Journal of Pharmaceutical Research and Applications
Volume 10, Issue 4 July-Aug 2025, pp: 466-481 www.ijprajournal.com ISSN: 2456-4494

family. India, Africa, and Southeast Asia are among the tropical and subtropical locations where it is extensively found. As illustrated in figure 1, the plant's many parts have long been used in Ayurvedic and traditional medicine to treat conditions like arthritis, asthma, and hypertension.

Figure 1. Different parts of Achyranthes aspera

Numerous bioactive substances, such as alkaloids (like achyranthine), flavonoids (such quercetin and kaempferol), saponins, and triterpenoids, have been found in A. aspera through phytochemical investigations. These components exhibit a range of pharmacological effects, the most notable of which are anti-inflammatory and antioxidant. Recent in vitro studies have indicated that methanolic extracts of A. aspera have potent anti-inflammatory activities, as evidenced by their capacity to inhibit lipoxygenase activity and albumin denaturation. Methanolic extracts of A. aspera have substantial anti-inflammatory capabilities because they inhibit albumin denaturation and lipoxygenase activity, according to current studies. These extracts have also demonstrated strong antioxidant qualities, indicating that they may be able to lessen cardiovascular disorders brought on by oxidative stress. (Chakraborty et al., 2002)

Phytochemical Profile of Achyranthes aspera

Ayurveda and other medical systems have long used A. aspera Linn., a widely distributed medicinal plant in the Amaranthaceae family, to treat a variety of illnesses, such as heart conditions. The plant is well-known for a wide range of bioactive components that support its therapeutic potential, especially its anti-inflammatory and antioxidant qualities that are important for the treatment of cardiovascular disease (CVD). (Desta, 1993)

Major Phytochemical Constituents

Several phytochemicals have been identified and characterized in different parts (leaves, roots, stems, seeds) of Achyranthes aspera, including:

- **Alkaloids** known for anti-inflammatory, antihypertensive, and cardioprotective effects.
- **Flavonoids**act as strong antioxidants, reducing oxidative stress linked to atherosclerosis and cardiac damage and scavenging free radicals.
- **Saponins**contribute to cardiovascular health by having lipid-lowering and anti-inflammatory qualities.
- **Triterpenoids**show anti-inflammatory and vasodilatory actions by modulating inflammatory mediators and endothelial functions.
- **Phenolic Compounds**display strong antioxidant properties by inhibiting lipid peroxidation and protecting endothelial cells from oxidative injury.

Table 1. Phytochemicals extracted from Achyranthes aspera

Phytochemical Class	Chemical Composition / Nature	Chemical Compounds
Alkaloids	Nitrogen-containing basic compounds with diverse pharmacological activities	Achyranthine, Betaine, Ecdysterone, Ecdysone
Flavonoids	Polyphenolic substances have antioxidant and anti-inflammatory effects.	Quercetin, Rutin, Kaempferol, Apigenin, Tiliroside,Achyasperoside
Saponins	Glycosides with surfactant properties, contributing to various biological effects	Oleanolic acid derivatives
Triterpenoids	Compounds derived from isoprene units, often exhibiting anti-inflammatory and antioxidant activities	Lupeol, Oleanolic acid, Betulinic acid

International Journal of Pharmaceutical Research and Applications
Volume 10, Issue 4 July-Aug 2025, pp: 466-481 www.ijprajournal.com ISSN: 2456-4494

Phenolic Compounds	Aromatic compounds with hydroxyl groups, known for antioxidant capabilities	Salicylic acid, caffeine, Quinic acid, ferulic acid, chlorogenic acid, protocatechuic acid, and Gentisic acid.
Sterols	Steroid alcohols contributing to membrane structure and function	β-Sitosterol, Stigmasterol
Fatty Acids and Esters	Long-chain carboxylic acids and their esters, involved in various metabolic processes	9,12-Octadecadienoic acid (Linoleic acid), Hexadecanoic acid (Palmitic acid), Squalene
Volatile Compounds	Low molecular weight compounds contributing to aroma and potential therapeutic effects	Phytol, Patchouli alcohol, Xanthoxylin, Benzaldehyde derivatives
Glycosides	Compounds where sugars are bound to other functional groups, often impacting solubility and bioavailability	Flavonoid C-glycosides (e.g., Achyasperoside), Phenylethanoid glycosides

These phytochemicals work together to treat cardiovascular tissues by blocking inflammatory cytokines, reducing oxidative stress indicators (e.g. MDA), and modifying pathways like NF-κB, COX-2, and iNOS. (Dey, 2011)

Analytical Techniques Used for Identification

In the past few years (2020–2024), researchers have employed several advanced techniques to isolate, identify, and quantify the bioactive compounds in Achyranthes aspera. These include:

- **HPLC Method**: Utilized for the quantitative examination of alkaloids, phenolic acids, and flavonoids. HPLC is frequently used to quantitatively analyze Achyranthes aspera's flavonoids, phenolic acids, and alkaloids. To identify flavonoids including luteolin, myricetin, quercetin, and kaempferol in methanolic extracts of A. aspera, Talreja et al. employed reversed-phase HPLC using a C18 column and UV detection at 339 nm. Using a methanol-water mobile phase in different ratios throughout a 35-minute run time, the separation was accomplished. (Gokhale et al., 2002)

- **Liquid Chromatography&Mass Spectrometry (LC-MS/MS)**: For identifying small components in complicated extracts and clarifying their structures. For the structural elucidation and profiling of minor elements in complex plant extracts, LC-MS/MS is an effective approach. Although there aren't many particular LC-MS/MS research on A. aspera, comparable methods have been used, such as UHPLC-HRMS. To help forecast their pharmacological targets through network pharmacology analysis, one study used UHPLC-HRMS to detect phenolic and flavonoid components in A. aspera preparations. (Han et al., 2001)

- **Gas Chromatography–Mass Spectrometry (GC-MS)**: Especially suitable for volatile components found in root and seed extracts. GC-MS is particularly useful for determining the volatile elements of A. aspera root and seed extracts. Varadharaj found chemicals such as phytol (22.13%), 9,12-octadecadienoic acid (12.74%), lupeol (1.74%), and squalene (0.55%) in hydro-alcoholic extracts of the entire plant. Another study found phytol (21.99%) and linoleic acid (13.74%) in methanolic leaf extracts, demonstrating the plant's diverse volatile profile. (Hariharan & Rangaswami, 1970)

- **NMR Spectroscopy Analysis**: Used to study the structural properties of isolated triterpenoids and saponins. NMR spectroscopy is useful in determining the structural properties of isolated triterpenoids and saponins from A. aspera. While the provided sources do not go into detail about specific NMR studies on A. aspera, NMR remains a standard technique for elucidating the structures of complex phytochemicals, including triterpenoids such as betulinic acid and oleanolic acid, which have been identified in the plant using other analytical methods.

- **FTIR Method**: For functional group analysis. FTIR analysis is useful in detecting functional

International Journal of Pharmaceutical Research and Applications
Volume 10, Issue 4 July-Aug 2025, pp: 466-481 www.ijprajournal.com ISSN: 2456-4494

groups in plant extracts. In a study by Qureshi and Solanki, FTIR spectra of A. aspera leaf extracts revealed peaks corresponding to functional groups such as hydroxyl (-OH), carbonyl (C=O), and aliphatic chains, indicating the presence of alcohols, esters, and other bioactive chemicals. (Kamisoyama et al., 2008)

- **UV–Visible Spectrophotometry**: These techniques used with the DPPH, ABTS, and FRAP tests to measure antioxidant activity indirectly by measuring levels of total phenolic and flavonoid compounds. UV-Visible spectrophotometry is often used to indirectly assess antioxidant activity by determining total phenolic and flavonoid levels. Using the Folin-Ciocalteu technique, which measures absorbance at 550 nm, the total phenolic content of A. aspera leaf extracts was evaluated. The findings revealed substantial antioxidant activity, which linked to the presence of phenolic compounds. (Kayani et al., 2008)

Pathogenesis of Inflammation and Cardiovascular Disease

CVD is one of the leading causes of death worldwide, with risk factors including hypertension, hyperlipidemia, diabetes, and smoking. However, new evidence firmly supports the importance of persistent low-grade inflammation in the development and progression of a variety of cardiovascular diseases, particularly atherosclerosis. Inflammation-induced endothelial dysfunction is the first stage of atherogenesis, marked by increased adhesion molecules and immune cell migration, particularly monocytes. These monocytes differentiate into macrophages, ingest oxidized low-density lipoproteins (oxLDL), and produce foam cells, which are early markers of plaque formation. (Khanna, 1992)

The NLRP3 inflammasome's activation intensifies the inflammatory process by causing the synthesis of pro-inflammatory cytokines. T lymphocytes penetrate the lesion and secrete interferon-gamma (IFN-γ), aggravating local inflammation. Dysfunctional regulatory T cells do not dampen this response. Vascular smooth muscle cells migrate into the intima, helping to build a fibrous cap and maintain plaque stability. Persistent inflammation, on the other hand, can cause matrix degradation, fibrous cap thinning, and plaque rupture, all of which can induce acute cardiovascular events like myocardial infarction or stroke. (Kothapalli et al., 2016)

Systemic inflammatory diseases and oxidative stress exacerbate endothelial dysfunction and nitric oxide depletion. Recent clinical trials, such as CANTOS and COLCOT, have shown that anti-inflammatory medicines including IL-1β inhibitors and colchicine can reduce cardiovascular risk. As researchers continue to investigate the complex relationship between immune activation and vascular disease, addressing inflammation appears to be a promising way to supplement traditional cardiovascular therapy. Understanding these pathways is critical for creating novel, more effective treatments for CVD. (Kumar, 1982)

Cardiovascular disorders (CVDs), including atherosclerosis, myocardial infarction, and heart failure, have long been linked to abnormal lipid metabolism and hemodynamic variables. However, growing evidence points to persistent inflammation as a key factor to their pathophysiology. Inflammatory mediators, notably cytokines and transcription factors, have an important role in regulating vascular integrity, lipid management, and immune cell infiltration, which eventually leads to endothelial dysfunction, plaque formation, and cardiovascular disease. (Kumar, Rajkumar, & Kanimozhi, 2010)

Role of Cytokines like IL-6, TNF-α, and CRP in CVD

Cardiovascular disorders (CVDs) have long been linked to abnormal lipid metabolism and hemodynamic. However, growing data suggests that chronic inflammation plays a critical role in their etiology. Inflammatory mediators, notably cytokines and transcription factors, have an important role in regulating vascular integrity, lipid management, and immune cell infiltration, which can contribute to endothelial dysfunction, plaque formation, and cardiovascular disease. The IL-6-induced production of CRP, a sensitive indicator of systemic inflammation, has been linked to an increased risk of peripheral artery disease, myocardial infarction, and stroke. Together, these chemicals induce atherosclerosis, thrombosis, and plaque rupture, raising the risk of cardiovascular events. Targeting these cytokines could be a useful therapeutic technique for lowering inflammation and improving cardiovascular outcomes. (Mailloux et al., 2010)

Inflammatory cytokines act as messengers of immune activation and perpetuate vascular injury in CVD.

International Journal of Pharmaceutical Research and Applications
Volume 10, Issue 4 July-Aug 2025, pp: 466-481 www.ijprajournal.com ISSN: 2456-4494

- Interleukin-6 is a pleiotropic cytokine that responds to infection, oxidative stress, and tissue damage, and is essential for the acute phase response. IL-6 causes hepatocytes to create C-reactive protein (CRP), an inflammatory biomarker that is closely linked to increased cardiovascular risk. In atherosclerotic plaques, IL-6 also promotes the development of smooth muscle cells and the migration of monocytes to the vascular endothelium.
- TNF-α is a strong pro-inflammatory cytokine that contributes to early atherogenesis. TNF-α promotes leukocyte adherence and transmigration to the subendothelial area by upregulating endothelial cell production of adhesion molecules such VCAM-1 and ICAM-1.
- TNF-α increases oxidative stress, endothelial apoptosis, and vascular smooth muscle proliferation, all of which indicate plaque instability.
- C-Reactive Protein (CRP) is now acknowledged as a direct contributor to vascular disease, while being formerly thought of as a mere marker of inflammation. CRP can increase monocyte recruitment, reduce endothelial nitric oxide (NO) bioavailability, and promote tissue factor expression, hence enhancing thrombotic potential. Elevated CRP levels have been linked to poor cardiovascular outcomes, making it a useful prognostic diagnostic.

NF-κB Signaling Pathway in Inflammatory Cardiovascular Events

The NF-κB pathway regulates inflammation and can be activated by numerous stimuli such as oxidative stress, changed lipoproteins, and pro-inflammatory cytokines. IκB, an inhibitor of NF-κB, prevents it from activating in resting cells. Degradation of IκB upon activation permits NF-κB to go into the nucleus and trigger the transcription of many pro-inflammatory genes and MMPs. (Manjula, Indira, & Dhasarathan, 2009)

Facilitating Immune Cell Infiltration

ICAM-1, VCAM-1, and E-selectin are among the cell adhesion molecules that are expressed more when NF-κB is activated in endothelial cells. These molecules are required to anchor circulating leukocytes to the vascular endothelium. NF-κB stimulates the expression of chemokines, including MCP-1 and RANTES, which attract monocytes and lymphocytes. Collectively, these signals drive immune cell transmigration into the sub-endothelial region, which contributes to persistent vascular inflammation. This persistent infiltration promotes a pro-inflammatory milieu, exacerbating endothelial dysfunction and initiating the formation of atherosclerotic plaques. (Manjula, Indira, & Dhasarathan, 2009)

Induction of Vascular Smooth Muscle Cell Proliferation and Endothelial Cell Apoptosis

NF-κB signaling plays a paradoxical role in vascular biology, triggering death in endothelial cells while encouraging VSMC growth. NF-κB promotes apoptosis in endothelial cells by upregulating genes such Fas ligand, Bax, and caspases, resulting in cell death. This weakens the arterial lining, exposing the subendothelial matrix to circulating lipoproteins and inflammatory mediators. In contrast, NF-κB promotes VSMC proliferation by activating cyclin D1, c-myc, and growth factors. This causes intimal thickening, which is a sign of vascular remodeling in hypertension and post-angioplasty restenosis. The combined occurrence of endothelial cell loss and VSMC proliferation impairs vascular homeostasis and hastens plaque formation. (Nakai et al., 2005)

Enhancement of Matrix Metalloproteinase (MMP) Activity

Matrix metalloproteinases (MMPs), particularly MMP-2 and MMP-9, are regulated by NF-κB in cardiovascular disease. The fibrous cap of atherosclerotic plaques contains collagen and elastin, two of the several extracellular matrix (ECM) components that are broken down by these enzymes. NF-κB-driven MMP overexpression decreases plaque structural integrity, making them susceptible to rupture. Plaque rupture exposes thrombogenic components like collagen and tissue factor to circulating platelets, which might result in an acute thrombotic event like myocardial infarction or ischemic stroke. When atherosclerotic plaques change from stable to unstable, NF-κB-induced MMP activity is crucial, and controlling it may have therapeutic ramifications. (Nakai et al., 2005)

Pro-thrombotic States in Tissue Factor (TF) Expression

NF-κB regulates thrombogenesis inside the vasculature. It increases the expression of tissue factor (TF), a powerful starter of the extrinsic

International Journal of Pharmaceutical Research and Applications
Volume 10, Issue 4 July-Aug 2025, pp: 466-481 www.ijprajournal.com ISSN: 2456-4494

coagulation cascade, in endothelial cells, macrophages, and VSMCs. Upregulation of TF in inflammatory circumstances causes enhanced thrombin production and consequent fibrin deposition, increasing the chance of intravascular clotting. Elevated TF levels, especially at the site of burst plaques, play a significant role in acute coronary thrombosis, the leading cause of sudden cardiac mortality. NF-κB-mediated TF expression is a critical link between inflammation and thrombosis, emphasizing its importance in cardiovascular events. (Nwune, Milala, & Zanna, 2017)
NF-κB activity has been consistently observed in atherosclerotic lesions and failing myocardium, suggesting its centrality in disease progression.

Macrophage Activation and Foam Cell Formation

Monocyte-derived macrophages are key effectors in atherogenesis. Upon recruitment to the intima, these cells differentiate and are activated by pro-inflammatory stimuli and modified low-density lipoproteins. (Nwune, Milala, & Zanna, 2017) Activated macrophages contribute to lesion formation through:

- Low-density lipoprotein phagocytosis causes foam cells to develop, which are hallmarkcomponents of the fatty streaks in early atherosclerotic lesions;
- Secretion of inflammatory cytokines that amplify local immune responses;
- Release of proteolytic enzymes and reactive oxygen species (ROS) that destabilize the plaque matrix;
- Promotion of necrotic core formation via apoptosis and defective efferocytosis, contributing to plaque vulnerability.

Moreover, different macrophage phenotypes (M1 pro-inflammatory vs. M2 anti-inflammatory) exhibit divergent roles in CVD. A dominance of M1 macrophages correlates with unstable plaques and adverse cardiovascular events.

Chronic Inflammation and Endothelial Dysfunction

Endothelial dysfunction is an early and important event in the progression of atherosclerosis, and it is closely associated with chronic low-grade inflammation.

- Chronic inflammation impairs nitric oxide (NO) synthesis, reducing vasodilation and promoting vasoconstriction and platelet aggregation.
- Persistent expression of cell adhesion molecules (CAMs) like VCAM-1 and ICAM-1 facilitates continued leukocyte adherence and transmigration.
- Inflammatory mediators increase vascular permeability, enabling lipid accumulation and immune cell infiltration in the subendothelial space.
- Endothelial cells adopt a pro-thrombotic and pro-inflammatory phenotype, promoting coagulation and inhibiting fibrinolysis.

Long-term inflammation exacerbates oxidative stress, mitochondrial malfunction, and autophagy dysregulation in endothelial cells, leading to senescence and death. These alterations weaken arterial integrity and promote atherosclerotic plaque formation and thrombosis, triggering cardiovascular events.
The anti-inflammatory properties of Achyranthes aspera have been substantiated through various experimental models:

- **Aqueous Extracts**:Aqueous extracts of Achyranthes aspera leaves and the whole plant were tested for their anti-inflammatory properties using the carrageenan-induced paw edema paradigm in albino mice. The extracts dramatically reduced edema, with the whole plant extract at 800 mg/kg acting more effectively than the conventional medication diclofenac sodium at 10 mg/kg. Flavonoids, alkaloids, saponins, and triterpenoids were found to be associated with this activity. (Pakrashi& Bhattacharya, 1977)

- **Methanolic Extracts**:Another study compared methanol and aqueous extracts of the aerial portions of Achyranthes aspera. Albumin denaturation inhibition and anti-lipoxygenase assays confirmed the methanol extract's stronger anti-inflammatory effect. This extract also showed significant antibacterial and thrombolytic activity. (Pakrashi& Bhattacharya, 1977)

- **Flavonoid C-Glycosides**:Four novel flavonoid C-glycosides were discovered in a chemical investigation using Achyranthes aspera's methanol extract. Compounds 2, 4, and 8-11 significantly inhibited nitric oxide generation in LPS-activated RAW264.7 cells (IC_{50} values ranged from 25.06 to 45.25

International Journal of Pharmaceutical Research and Applications
Volume 10, Issue 4 July-Aug 2025, pp: 466-481 www.ijprajournal.com ISSN: 2456-4494

μM). This suggests a potential function in moderating inflammatory responses. (Pandey et al., 2013) While direct studies on the cardiovascular effects of Achyranthes aspera are limited, its anti-inflammatory and thrombolytic properties suggest potential benefits:

- **Thrombolytic Activity**: The methanol extract of Achyranthes aspera showed 75.2% clot lysis at 1000 μg/mL, indicating its potential in managing thrombotic conditions.
- **Saponin-Rich Fraction**:A study found that the saponin-rich fraction of Achyranthes aspera had anti-inflammatory benefits in a rat arthritic model generated by adjuvants. Given that chronic inflammation is a risk factor for cardiovascular disease, these findings could have an impact on cardiovascular health. (Pandey et al., 2013)

Achyranthes asperahas considerable anti-inflammatory and thrombolytic properties, owing to its rich phytochemical makeup, which includes flavonoids, saponins, and alkaloids. While these features suggest potential therapeutic applications in inflammation and maybe cardiovascular problems, more clinical research is needed to fully understand its efficacy and safety profiles. (Raj et al., 2009)

Antioxidant Activity of Achyranthes aspera in Cardiovascular Tissues

The development of cardiovascular illnesses is significantly influenced by oxidative stress, which is brought on by an imbalance between the body's antioxidant defenses and the generation of ROS. Excess ROS in cardiovascular tissues kills endothelial cells, smooth muscle cells, and cardiomyocytes, which causes inflammation, mortality, and tissue remodeling.Achyranthes aspera Linn, a well-known medicinal plant, has several phytoconstituents that have potent antioxidant properties. These effects are achieved by both direct scavenging of free radicals and the strengthening of endogenous antioxidant defense mechanisms. (Reddy et al., 2011)

An overabundance of reactive oxygen species (ROS) and a deficiency in antioxidant defenses lead to oxidative stress, which is a major factor in the etiology of cardiovascular disorders. ROS-induced injury damages the endothelium, vascular smooth muscle cells (VSMCs), and cardiomyocytes, contributing to atherosclerosis, ischemia-reperfusion injury, and heart failure.Achyranthes aspera Linn., a plant with ethnomedicinal value, has many bioactive components with promising antioxidant pathways, suggesting therapeutic promise against CVD-related oxidative damage. (Sandhyakumary et al., 2002)

Role of Phytochemicals in Scavenging ROS and Enhancing Endogenous Antioxidant Activity

Betaine, N-trans-feruloyltyramine, and plant-derived polysaccharides (commonly known as ABPS) are among the prominent elements of Achyranthes aspera that play important roles in oxidative stress reduction. Betaine is an efficient osmoprotectant and methyl donor that directly neutralizes ROS like superoxide anions and hydroxyl radicals. It also increases the expression of essential antioxidant enzymespromoting cellular redox equilibrium. N-trans-feruloyltyramine, a phenolic amide, exhibits both antioxidant and anti-inflammatory properties. (Saravanan et al., 2008) It effectively scavenges lipid peroxyl radicals, inhibits lipid peroxidation, and reduces malondialdehyde (MDA) formation, a known indicator of oxidative damage. Furthermore, it activates the Nrf2 signaling pathway, which promotes the transcription of detoxifying and antioxidant genes like HO-1, GPx, and SOD. Similarly, ABPS has hydroxyl radical scavenging activity and dramatically lowers ROS generation in both endothelial and cardiac cells. These polysaccharides also influence redox-sensitive signaling pathways like as MAPK and PI3K/Akt, which are required for cardiovascular protection and cellular survival in oxidative environments. (Seshadri et al., 1981)

Mitochondrial Protection and Inhibition of Cytochrome C Release

Mitochondria are not only the main producer of ROS in cardiovascular tissues, but they are also extremely vulnerable to oxidative injury. Loss of membrane potential (ΔΨm) due to mitochondrial dysfunction triggers the release of cytochrome C, which starts the apoptotic cascade, when mitochondrial permeability transition pores (mPTP) open. Achyranthes aspera phytochemicals, such as betaine and N-trans-feruloyltyramine, support mitochondrial integrity by inhibiting cytochrome c release and maintaining ΔΨm. (Saravanan et al., 2008) This activity inhibits caspase-9 and caspase-3 activation, which reduces apoptosis in cardiomyocytes and vascular endothelial cells. Furthermore, these substances boost the action of mitochondrial antioxidants such

International Journal of Pharmaceutical Research and Applications
Volume 10, Issue 4 July-Aug 2025, pp: 466-481 www.ijprajournal.com ISSN: 2456-4494

manganese superoxide dismutase (Mn-SOD), reducing the accumulation of mitochondria-derived ROS. Such mitochondrial protection is vital in the management of ischemia-reperfusion injury, heart failure, and other oxidative stress-related cardiovascular conditions. (Seshadri et al., 1981)

Synergistic Interactions of Flavonoids and Alkaloids in Endothelial Antioxidant Activity

Achyranthes aspera contains flavonoids and alkaloids, which work together to form a synergistic antioxidant mechanism, notably in endothelial cells. Flavonoids are powerful electron donors that neutralize ROS, but alkaloids inhibit enzymes like NADPH oxidase, a primary cause of oxidative stress in vascular tissues. Furthermore, flavonoids promote the development of eNOS, boosting NO production, which has vasodilatory and antioxidant characteristics. Meanwhile, alkaloids protect cellular membranes and decrease lipid peroxidation. (Singh, Singh, Navneet, & Srivastava, 2018) These chemicals stimulate intracellular antioxidant pathways, including the Nrf2/Keap1 and NF-κB signaling cascades, providing full protection against oxidative damage. Experimental evidence from in vitro experiments using endothelial cell cultures shows that flavonoid-alkaloid combos reduce intracellular ROS levels, increase GSH content, and prevent apoptosis more efficiently than single compounds. These data suggest that optimizing phytochemical combinations or nanoparticle-based delivery strategies could increase antioxidant activity.

Modulation of Inflammatory Pathways in Atherosclerosis

Atherosclerosis, a chronic inflammatory condition affecting the artery wall, is a major contributor to cardiovascular disease. Atherosclerosis is caused by oxidative stress, lipid buildup, and persistent inflammation, which eventually lead to plaque formation and arterial blockage. New research reveals that Achyranthes aspera Linn, a medicinal herb used in Ayurveda and ethnomedicine, may have considerable therapeutic effects by modifying inflammatory pathways at several stages of the atherosclerotic process. (Singh, Singh, Navneet, & Srivastava, 2018)

NF-κB and NLRP3 Inflammasome Inhibition

NF-κB, a transcription factor that controls the production of pro-inflammatory genes including TNF-α and IL-6, is activated when atherogenesis occurs. These cytokines cause endothelial dysfunction by promoting leukocyte adherence and transmigration into the artery intima. Achyranthes aspera's bioactive components, including flavonoids and alkaloids, have been shown to reduce NF-κB activation. TNF-α and IL-6 transcription levels are decreased by A. aspera extract's inhibition of NF-κB translocation to the nucleus, according to in vitro studies. Furthermore, the NOD-like receptor family pyrin domain-containing 3 (NLRP3) inflammasome has been prevented from activating by its triterpenoid saponins. This is a crucial component in the creation of mature IL-1β and IL-18, pivotal cytokines in vascular inflammation. (Srivastav, Singh, Mishra, Jha, & Khosa, 2011a)

Immune Cell Regulation

A. aspera regulates both innate and adaptive immune responses. The herb aids macrophages in changing their M1 phenotype, which promotes inflammation, to M2, which inhibits inflammation. This shift is crucial for decreasing inflammation and promoting tissue repair in atherosclerotic plaques. Furthermore, ethanol extracts of A. aspera have been demonstrated to regulate T lymphocyte function by increasing regulatory T cell (Treg) responses and decreasing Th1-mediated pro-inflammatory cytokine secretion. This combined impact adds to an immune environment that promotes vascular homeostasis while slowing lesion progression. (Srivastav, Singh, Mishra, Jha, & Khosa, 2011b)

Plaque Stabilization via Saponin-Mediated Pathways

Plaque instability is an important risk factor for acute coronary events. The fibrous cap of atherosclerotic plaques is weakened by matrix metalloproteinases (MMPs), particularly MMP-9, which also break down extracellular matrix components, increasing the risk of rupture. Saponins from A. aspera may decrease NF-κB and MAPK pathways, reducing MMP-9 synthesis and activity. A. aspera also inhibits two important mediators of monocyte attachment and penetration into the vascular intima: vascular cell adhesion molecule-1 (VCAM-1) and intercellular adhesion molecule-1 (ICAM-1). This anti-adhesive activity is ascribed to phytochemicals such betaine, ecdysterone, and oleanolic acid, which jointly inhibit endothelium activation. (Sutar et al., 2008)

Targeting Hypertension Through Dual Antioxidant-Anti-inflammatory Actions

Cardiovascular diseases (CVDs), particularly hypertension, are caused by a complex

International Journal of Pharmaceutical Research and Applications
Volume 10, Issue 4 July-Aug 2025, pp: 466-481 www.ijprajournal.com ISSN: 2456-4494

interaction of oxidative stress and chronic inflammation. Therapeutic methods that target both of these pathways provide a promising alternative to standard monotherapy. Achyranthes aspera Linn., a well-known medicinal herb in Ayurveda and traditional medicine, exhibits potential due to its high concentration of phytoconstituents that have both antioxidant and anti-inflammatory properties. (Tandon & Rao, 1966) This section explores the mechanistic role of Achyranthes aspera in modulating hypertension via key molecular targets:

Endothelial Nitric Oxide Synthase (eNOS) Activation

One of the hallmarks of hypertension is endothelial dysfunction, characterized by impaired nitric oxide (NO) bioavailability. Achyranthes aspera exerts protective vascular effects by restoring endothelial function through the activation of eNOS. (Tiwari & Talreja, 2020a) Bioactive compounds such as betaine and hydroxyproline (HYP) alkaloids identified in the aerial parts of the plant have shown to:

- Enhance eNOS phosphorylation at Ser1177, promoting NO production.
- Protect endothelial cells from oxidative damage induced by ROS.
- Reduce vascular resistance, thereby normalizing blood pressure.

Preclinical studies suggest that aqueous and ethanolic extracts of A. aspera significantly increase NO levels and improve endothelial relaxation in hypertensive rat models. This supports its potential as a natural NO donor or eNOS enhancer in the management of vascular tone.

ACE Inhibition as Flavonoid-Mediated Suppression

In order to regulate blood pressure, the renin-angiotensin-aldosterone system (RAAS) is crucial. The vasoconstrictor angiotensin II is produced from angiotensin I by the angiotensin-converting enzyme (ACE).(Tiwari & Talreja, 2020a)Achyranthes aspera contains flavonoids such as quercetin and kaempferol derivatives, which exhibit potent ACE inhibitory activity:

- In vitro assays reveal IC_{50} values of A. aspera extracts comparable to synthetic ACE inhibitors like captopril.
- Flavonoids act by chelating the zinc ion at the active site of ACE, leading to reversible inhibition.
- Reduction in angiotensin II levels contributes to vasodilation and decreased aldosterone secretion, mitigating hypertensive stress.

Calcium Overload Prevention in Vascular Smooth Muscle Cells (VSMCs)

Intracellular calcium overload is a critical contributor to vascular smooth muscle cell (VSMC) contraction, proliferation, and ultimately, vascular remodeling associated with hypertension. A. aspera has demonstrated a capacity to regulate calcium homeostasis by:

- Inhibiting L-type calcium channels, thereby reducing calcium influx in VSMCs.
- Suppressing IP_3 -mediated calcium release from the sarcoplasmic reticulum.
- Downregulating the expression of pro-contractile markers like calmodulin and myosin light chain kinase (MLCK).

This modulation of calcium dynamics prevents VSMC hypertrophy and maintains vascular elasticity, essential for normalizing elevated blood pressure and preventing long-term cardiovascular damage.

Achyranthes aspera's combination of antioxidant and anti-inflammatory mechanisms provides a synergistic approach for hypertension control. The plant's bioactive ingredients interact with several molecular targets, including the eNOS, ACE, and calcium signaling pathways, indicating its potential as a multifunctional phytomedicine. (Tiwari & Talreja, 2020b)

Thrombolytic and Antiplatelet Potential of Achyranthes aspera

Cardiovascular diseases (CVDs), which are predominantly caused by thrombotic complications and atherogenic events, demand treatment techniques that aim to minimize clot formation and increase fibrinolytic activity. In this context, Achyranthes aspera Linn has emerged as a promising ethnomedicinal plant with considerable thrombolytic and antiplatelet properties that may provide cardioprotection by lowering clot load and inhibiting platelet aggregation. (Tullanithi, Sharmila, &Gnanendra, 2010)

Clotlysis mechanisms

Fibrinolysis is a physiological mechanism that breaks down fibrin clots and restores normal blood flow. In vitro studies showed that A. aspera's methanolic extract has significant fibrinolytic activity. According to a recent study, at a

International Journal of Pharmaceutical Research and Applications
Volume 10, Issue 4 July-Aug 2025, pp: 466-481 www.ijprajournal.com ISSN: 2456-4494

concentration of 25 mg/mL, the extract had a 15.35% clot lysis capacity, indicating that it has the potential to destroy fibrin networks and aid in thrombus resolution. The presence of phytoconstituents may be responsible for this thrombolytic effect. It has been shown that these compounds change the action of natural fibrinolytic factors such urokinase-type plasminogen activator (u-PA) and tissue plasminogen activator (t-PA). These substances could also help plasminogen be converted into plasmin, the main enzyme that breaks down fibrin. (Udayan et al., 2006)

Platelet aggregation inhibition

Platelet aggregation is a key factor in the development of thrombosis and myocardial infarction. Inhibiting platelet aggregation is thus an important method in avoiding CVD development. Achyranthes aspera has been shown to have antiplatelet effects by modulating critical enzymatic pathways. Terpenoids found in the plant can inhibit COX-1, reducing the production of TXA_2 , a strong vasoconstrictor and platelet aggregator. A. aspera's downregulation of the COX-1/TXA_2 axis lowers platelet activation and aggregation, adding to its cardioprotective effects. (Valsaraj et al., 1997)

A. aspera inhibits platelet aggregation in the same way that traditional antiplatelet drugs, such as aspirin, do, albeit more extensive clinical and mechanistic research are needed. Terpenoids may also influence intracellular calcium mobilization and glycoprotein IIb/IIIa receptor expression, hence inhibiting platelet activation. (Vasudeva & Sharma, 2006)

Table 2. Thrombolytic and Antiplatelet Effects of Achyranthes aspera Linn

Parameter	Observed Activity	Active Phytoconstituents	Proposed Mechanism
Clot Lysis (25 mg/mL)	15.35% fibrinolytic activity	Saponins, flavonoids, phenolics	Activation of plasmin, degradation of fibrin
Platelet Aggregation Inhibition	Significant inhibition via COX-1 pathway	Terpenoids	Inhibition of COX-1, reduction in TXA_2 synthesis
Comparative Efficacy	Moderate, aspirin-like effects	Terpenoids, alkaloids	Attenuation of intracellular signaling and calcium mobilization

Nanotechnology-Driven Delivery Systems

The administration of phytoconstituents has been transformed by recent developments in nanotechnology, especially in terms of improving their pharmacokinetics and pharmacodynamics for cardiovascular applications. Several bioactive substances, including ecdysterone and indole-3-carboxaldehyde, which are prone to breakdown and fast metabolism, are found in Achyranthes aspera Linn, a medicinal plant with well-established anti-inflammatory and antioxidant qualities. Combining nanotechnology with phytotherapy is a viable way around these restrictions. (Vetrichelvan & Jegadeesan, 2003)

Liposomal encapsulation for heat labile alkaloids

An effective method for encapsulating heat-sensitive alkaloids, including indole-3-carboxaldehyde, a crucial bioactive found in A. aspera, is liposomal systems. This indole derivative has strong cytoprotective and antioxidant properties that help reduce endothelial dysfunction brought on by oxidative stress, which is a major step in the development of atherosclerosis. (Storm & Crommelin, 1998) Phospholipid bilayers make up liposomes, which shield thermolabile components from harsh gastrointestinal conditions and enzymatic breakdown. Research has indicated that liposomal encapsulation considerably improves phytochemicals' oral bioavailability, half-life, and target tissue retention. Liposomal preparations of plant-derived alkaloids have demonstrated improved vascular tissue penetration in cardiovascular models, which has improved the therapeutic efficacy against inflammatory indicators including VCAM-1, ICAM-1, and CRP. (Rudzińska et al., 2024)

International Journal of Pharmaceutical Research and Applications
Volume 10, Issue 4 July-Aug 2025, pp: 466-481 www.ijprajournal.com ISSN: 2456-4494

Table 3. Advantages of Liposomal Encapsulation for A. aspera Alkaloids

Parameter	Conventional Extracts	Liposomal Encapsulation
Stability of indole derivatives	Low	High
Oral bioavailability	Moderate	Enhanced (~2-3 fold)
Protection from degradation	No	Yes
Endothelial uptake	Limited	Improved
Anti-inflammatory marker control	Mild	Significant

Targeted nanoparticles using functionalized carriers

A new strategy uses functionalized nanoparticles designed to transport active phytoconstituents to sick or inflammatory cardiovascular tissues, especially atherosclerotic plaques. Using ligands like antibodies, peptides (like RGD), or folic acid, these nanoparticles can be surface-functionalized to target macrophages in plaques or overexpressed receptors in vascular endothelium. (Shukla et al., 2017) Adding antioxidants to polymeric nanoparticles (such PLGA or chitosan-based systems) in the setting of A. aspera offers a number of advantages, including accumulation at inflammatory vascular sites, protection against first-pass metabolism, and prolonged release.(Chaudhary et al., 2022) Key pathological factors to atherogenesis, such as reduced ROS generation, decreased foam cell formation, and localized suppression of the NF-κB pathway, are all achieved through targeted administration. The combination of A. aspera's hydrophobic and hydrophilic fractions is made possible by hybrid nanocarriers such lipid-polymer nanoparticles (LPNs), which optimizes the plant's overall therapeutic profile. (Peng et al., 2022)



Figure 1. Mechanism of site-specific targeting of phytoconstituents by functionalized nanoparticles

International Journal of Pharmaceutical Research and Applications
Volume 10, Issue 4 July-Aug 2025, pp: 466-481 www.ijprajournal.com ISSN: 2456-4494

Cardioprotective Mechanisms of Achyranthes aspera

The investigation of medicinal plants in cardiovascular pharmacology has accelerated because of their multi-targeted therapeutic potential and rich phytochemical profiles. Because of its anti-inflammatory and antioxidant qualities, Achyranthes aspera Linn., a plant that is frequently used in traditional medicine, has significant cardioprotective effects. Its modes of action are described in this section, with special attention to cardiovascular health and disease. (Sharma & Sharma, 1997)

Anti-atherogenic Effects on Lipid Profile and Endothelial Protection

Atherosclerosis is a major cause of cardiovascular morbidity and is typified by lipid buildup, endothelial dysfunction, and persistent vascular inflammation. By regulating lipid metabolism and promoting endothelium integrity, Achyranthes aspera has shown notable anti-atherogenic qualities. Research conducted on animal models with hyperlipidemia demonstrates that the treatment of Achyranthes aspera results in a rise in high-density lipoprotein cholesterol (HDL-C) and a decrease in triglycerides (TG), total cholesterol (TC), and low-density lipoprotein cholesterol (LDL-C). The plant's saponins, flavonoids, and alkaloids, which increase the expression of hepatic LDL receptors and inhibit HMG-CoA reductase activity, are probably responsible for these effects. (Jiang et al., 2024) By decreasing oxidative stress indicators like malondialdehyde (MDA) and raising nitric oxide (NO) bioavailability, Achyranthes aspera not only lowers cholesterol but also protects endothelium. Endothelial dysfunction, a crucial early step in atherogenesis, is lessened as a result.

Vasodilatory and Hypotensive Properties of Achyranthes aspera

One of the main risk factors for cardiovascular problems is hypertension. Achyranthes aspera may be useful as a natural antihypertensive agent because of its vasodilatory and blood pressure-lowering properties. Through both endothelium-dependent and -independent processes, Achyranthes aspera's alcoholic and aqueous extracts encourage vasodilation. This is mostly accomplished by inhibiting calcium influx in vascular smooth muscle cells and producing more prostacyclin (PGI_2) and nitric oxide (NO). (Laridi et al., 2003) Moreover, the plant's flavonoids and alkaloids may directly alter vascular tone. Chronic administration of A. aspera extract dramatically decreased mean arterial pressure, diastolic, and systolic pressure in animal models of hypertension. This effect was probably caused by natriuresis and interactions with angiotensin-converting enzyme (ACE) pathways. (Trucillo et al., 2020)

Improvement in Cardiac Biomarkers in Treated Animal Models

Biomarkers are frequently used to evaluate heart damage and necrosis. Achyranthes aspera dramatically reduces the elevation of these markers, indicating cardiomyocyte membrane stability and decreased necrosis, according to experimental research using isoproterenol or doxorubicin-induced cardiotoxicity models. (Xu et al., 2023) Aspera's antioxidant properties are crucial for heart health since they upregulate the enzymes glutathione peroxidase (GPx), catalase (CAT), and superoxide dismutase (SOD). Improved cellular viability in the myocardium is also a result of stabilizing lysosomal enzymes and lowering lipid peroxidation. (Lakkis, 2007)

Function in Models of Ischemia/Reperfusion Injury and Myocardial Infarction

These injury are central events in acute coronary syndromes, often exacerbated by oxidative stress and inflammation. Preclinical models have shown that Achyranthes aspera can mitigate myocardial damage in these settings. (Subramani & Ganapathyswamy, 2020) In I/R models, pre-treatment with A. aspera extract results in reduced infarct size, preservation of left ventricular function, and improvement in hemodynamic parameters. The underlying mechanisms include:

- Scavenging of ROS to prevent oxidative stress-induced apoptosis
- Inhibition of pro-inflammatory cytokines
- The downregulation of pro-apoptotic mediators (including caspases and Bax) and the upregulation of anti-apoptotic proteins (like Bcl-2)

In infarction models induced by isoproterenol or coronary ligation, Achyranthes aspera extract also reduces myocardial fibrosis and cellular infiltration, contributing to enhanced myocardial regeneration and functional recovery.

International Journal of Pharmaceutical Research and Applications
Volume 10, Issue 4 July-Aug 2025, pp: 466-481 www.ijprajournal.com ISSN: 2456-4494

II. FUTURE DIRECTIONS

The clinical acceptance of herbal remedies in cardiovascular therapy is hampered by a number of important research gaps, despite the encouraging preliminary evidence. The dearth of carefully planned clinical trials confirming the cardioprotective benefits of several phytoconstituents is among the most urgent issues. The majority of the evidence currently available has not been sufficiently translated into human trials and is restricted to in vitro assays or animal models. This disparity hinders regulatory approvals and broader clinical acceptability in addition to restricting the development of standardized dose and safety profiles.

The integration of molecular-level investigations, including as transcriptomics, proteomics, and molecular docking, which are essential for pinpointing the exact mechanisms of action of bioactive herbal constituents, is another aspect that has not received enough attention. Transcriptomic and proteomic profiling would assist in revealing the downstream signaling pathways and changes in gene/protein expression that are involved, while molecular docking studies can determine the possible binding affinity and interactions of phytochemicals with important cardiac receptors or enzymes. The absence of such mechanistic information hinders lead molecule optimization and adds to the uncertainty in therapeutic results.

The use of delivery systems based on nanotechnology, including nano-formulations, is still a new but underutilized strategy in the sector. Herbal bioactives' stability, bioavailability, and targeted delivery—especially to ischemic cardiac tissues—could be greatly enhanced by encapsulating them in nanoparticles, liposomes, or nanosponges. There is still little translational research from the bench to the bedside, despite promising in vitro results. Closing this gap may result in herbal formulations for the treatment of chronic cardiovascular illnesses that are more patient-friendly and effective.

Last but not least, diverse and disease-relevant experimental models that more closely resemble human pathophysiology are desperately needed. Current research frequently uses generic models for myocardial infarction or hypertension, which fall short in capturing the complexities of co-morbid disorders including aging, diabetes, and metabolic syndrome. Multi-factorial experimental models and perhaps human organoid-based systems should be the focus of future study since they can shed more light on toxicity and efficacy in physiologically realistic settings.

III. CONCLUSION

The increasing prevalence of cardiovascular diseases (CVDs) over the world necessitates a continuous quest for novel, efficient, and secure treatment approaches. Because of its extensive phytoconstituent profile and deep biological activity, Achyranthes aspera Linn., a traditionally valued medicinal herb, shows promise as a phytotherapeutic candidate. The plant's strong anti-inflammatory and antioxidant qualities have been thoroughly discussed in this review. These qualities are crucial to the etiology and development of a number of cardiovascular diseases, including hypertensive heart disorders, ischemic heart disease, and atherosclerosis. In preclinical models, the bioactive substances found in Achyranthes aspera—such as saponins, alkaloids, flavonoids, and phenolic acids—have shown significant pro-inflammatory mediator regulation, oxidative stress biomarker modification, and free radical scavenging activity.All of these actions point to a high potential for cardioprotection. Additionally, the plant's incorporation into contemporary complementary therapies for CVDs is supported by both its ethnomedicinal heritage and new scientific findings. Mechanistic studies, thorough in vivo investigations, promising preliminary findings, and carefully planned clinical trials are essential to confirming Achyranthes aspera's safety and effectiveness as a treatment for cardiovascular disorders in humans. New therapeutic insights and formulations generated from this herb can be discovered using a multidisciplinary approach that combines pharmacological, biochemical, molecular, and clinical research. This encourages the researchers to focus their scientific curiosity and rigor on investigating these historically important but neglected medicinal herbs. In a time when integrative medicine and phytotherapy are becoming more and more popular, investigating the complete pharmacological potential of plants like Achyranthes aspera may provide not just complementary but also alternative choices for the treatment of chronic illnesses like CVDs. By encouraging creativity, teamwork, and evidence-based investigation, the upcoming generation of researchers can help close the gap between conventional wisdom and contemporary treatments. As aspiring leaders in the medical and scientific fields, you will play a crucial part in creating a

International Journal of Pharmaceutical Research and Applications
Volume 10, Issue 4 July-Aug 2025, pp: 466-481 www.ijprajournal.com ISSN: 2456-4494

more sustainable and healthful future that is based on both science and tradition.

REFERENCES

[1]. Alagesboopathi, C. (2013). Ethnomedical plants used for the treatment of snake bite by Malayali tribes and rural people in Salem, Tamil Nadu, India. International Journal of Bioscience, 3(2), 42–53.

[2]. Bhattarai, N. K. (1992). Folk use of plants in veterinary medicine in Central Nepal. Fitoterapia, 63, 497–506.

[3]. Bir, S. S., & Sidhu. (1979). Cytological observations in weed flora of orchards of Patiala district, Punjab. Recent Research in Plant Science (New Delhi), 7, 261–271.

[4]. Chakraborty, A., Brantner, A., Mukuinaka, T., Nobukuni, Y., Kuchido, M., et al. (2002). Cancer chemopreventive activity of Achyranthes aspera leaves on Epstein–Barr virus activation and two-stage mouse skin carcinogenesis. Cancer Letters, 177(1), 1–5.

[5]. Desta, B. (1993). Antibacterial activity of aqueous flower extracts of Achyranthes aspera. Journal of Ethnopharmacology, 39, 129–139.

[6]. Dey, A. (2011). Achyranthes aspera L.: Phytochemical and pharmacological aspects. International Journal of Pharmaceutical Sciences Review and Research, 9(2), 72–82.

[7]. Gokhale, A. B., Damre, A. S., Kulkami, K. R., & Saraf, M. N. (2002). Preliminary evaluation of anti-inflammatory and anti-arthritic activity of S. lappa, A. speciosa and A. aspera. Phytomedicine, 9(5), 433–437.

[8]. Han, L. K., Kimura, Y., Kawashima, M., et al. (2001). Anti-obesity effects in rodents of dietary teasaponin, a lipase inhibitor. International Journal of Obesity, 25(10), 1459–1464.

[9]. Hariharan, V., & Rangaswami, S. (1970). Structure of saponins A and B from the seeds of Achyranthes aspera. Phytochemistry, 9(2), 409–414.

[10]. Kamisoyama, H., Honda, K., Tominaga, Y., Yokota, S., & Hasegawa, S. (2008). Investigation of the anti-obesity action of licorice flavonoid oil in diet-induced obese rats. Bioscience, Biotechnology and Biochemistry, 72(12), 3225–3231.

[11]. Kayani, S., Zia, M., Sarwar, S., Riaz-ur-Rehman, & Chaudhary, M. F. (2008). Callogenic studies of Achyranthes aspera leaf explant at different hormonal combinations. Pakistan Journal of Biological Sciences, 11(6), 950–952.

[12]. Khanna, N. M. (1992). Hypolipidemic activity of Achyranthes aspera Linn. in normal and Triton-induced hyperlipidemic rats. Journal of Experimental Biology, 30(2), 128–130.

[13]. Kothapalli, L., Gita, P. R., Thomas, A., & Nanda, R. (2016). Evaluation of antivenom potential of Achyranthes aspera leaves against snake venom. International Journal of Pharmaceutical and Drug Analysis, 4(12), 505–513.

[14]. Kumar, A. (1982). Polyploidy in Achyranthes aspera and Chrysanthemum leucanthemum. Acta Botanica Indica, 10, 141–142.

[15]. Kumar, A. P., Rajkumar, & Kanimozhi, M. (2010). Phytochemical screening and antimicrobial activity from five Indian medicinal plants against human pathogens. Middle-East Journal of Scientific Research, 5(6), 477–482.

[16]. Mailloux, J., Le Bellec, F., Kreiter, S., Tixier, M. S., & Dubois, P. (2010). Influence of ground cover management on diversity and density of phytoseiid mites (Acari: Phytoseiidae) in Guadeloupean citrus orchards. Experimental and Applied Acarology, 52(3), 275–290.

[17]. Manjula, M., Indira, V., & Dhasarathan, P. (2009). In vitro action of Coccinia grandis against bacterial organisms. Asian Journal of Microbiology, Biotechnology and Environmental Sciences, 11(2), 317–320.

[18]. Nakai, M., Fukui, Y., Asami, S., et al. (2005). Inhibitory effects of oolong tea polyphenols on pancreatic lipase in vitro. Journal of Agricultural and Food Chemistry, 53(11), 4593–4598.

[19]. Nwune, H. C., Milala, M. A., & Zanna, H. (2017). Effect of aqueous stem extract of Achyranthes aspera on Bitis arietans venom protease and phospholipase A2 activity. American Journal of BioScience, 5(3), 54–58.

[20]. Pakrashi, A., & Bhattacharya, N. (1977). Abortifacient principle of Achyranthes aspera Linn. Indian Journal of Experimental Biology, 15(10), 856–858.

[21]. Pandey, N. K., Sharma, H. P., Patnaik, A., & Jain, P. (2013). A review on potential magic folk herbal medicinal plant: Achyranthes aspera L. International Journal of Medicinal Plants, Photon 105, 350–363.

[22]. Raj, S. K., Snehi, S. K., Kumar, S., Pratap, D., & Khan, M. S. (2009). Association of 'Candidatus Phytoplasma asteris' (16SrI group) with yellows of Achyranthes aspera in India. Plant Pathology, 58, 390.

[23]. Reddy, T. R. M., Karunakar, B., & Vidyasagar, G. (2011). Seed volatile oil analysis and in vitro antimicrobial activity of potential medicinal herb: Achyranthes aspera (Willd). International Journal of Pharmacy & Technology, 3(1), 1860–1866.

[24]. Sandhyakumary, K., Boby, R. G., & Indira, M. (2002). Impact of feeding ethanolic extract of Achyranthes aspera Linn. on reproductive functions in male rats. Indian Journal of Experimental Biology, 40, 1307–1309.

[25]. Saravanan, P., Ramasamy, V., & Shivakumar, T. (2008). Antimicrobial activity of leaf extracts of Achyranthes aspera Linn. Asian Journal of Chemistry, 20(1), 823–825.

[26]. Seshadri, V., Batla, A. K., & Rangaswami, S. (1981). Structure of two new saponins from Achyranthes aspera. Indian Journal of Chemistry B, 20, 773–775.

[27]. Singh, S., Singh, S., Navneet, & Srivastava, V. (2018). Ethnobotanical and pharmacological benefits of Achyranthes aspera Linn: An overview. International Journal of Pharmaceutical Sciences Review and Research, 48(2), 1–7.

[28]. Chaudhary, J., Tyagi, A., Bhatt, S., Pathak, A., Rao, N. G. R., & Mittal, S. (2022). Applications of nanomaterials in improving the traditional diagnostic approach. Journal of Survey in Fisheries Sciences, 2368–7487, 191–206.

[29]. Srivastav, S., Singh, P., Mishra, G., Jha, K. K., & Khosa, R. L. (2011). Achyranthus aspera: An important medicinal plant—A review. Journal of Natural Products and Plant Resources, 1(1), 1–14.

[30]. Sutar, N. G., Sutar, U. N., Sharma, Y. P., Shaikh, I. K., & Kshirsagar, S. S. (2008). Phytochemical investigation and pharmacological screening of leaves of Achyranthes aspera Linn. as analgesic and antipyretic. Biosciences Biotechnology Research Asia, 5(2), 841–844.

[31]. Tandon, S. L., & Rao, G. R. (1966). Mechanism of evolution of higher chromosomal forms in some orchard weeds. Indian Journal of Horticulture, 23, 62–68.

[32]. Tiwari, D., & Talreja, S. (2020). A pharmacological and medicinal study of areca palm and nuts: An overview. Research Journal of Pharmaceutical, Biological and Chemical Sciences, 11(5), 100–108. https://doi.org/10.33887/rjpbcs/2020.11.5.12

[33]. Tiwari, D., & Talreja, S. (2020). Insomnia: A study on sleeping disorder with the reference of Ayurvedic herbs. Journal of Pharmaceutical Sciences and Research, 12(9), 1375–1379.

[34]. Tullanithi, K. M., Sharmila, B., &Gnanendra, T. S. (2010). Preliminary phytochemical analysis and antimicrobial activity of Achyranthes aspera Linn. International Journal of Biological Technology, 1(3), 35–38.

[35]. Udayan, P. S., George, S., Tushar, K. V., & Balachandran, I. (2006). Medicinal plants used by the Malayali tribe of Servarayan hills, Yercad, Salem district, Tamil Nadu, India. Zoos' Print Journal, 21(4), 2223–2224.

[36]. Valsaraj, R., Pushpangadan, P., Smitt, U. W., Andersen, A., & Nyman, U. (1997). Antimicrobial screening of selected medicinal plants from India. Journal of Ethnopharmacology, 58, 75–83.

[37]. Vasudeva, N., & Sharma, S. K. (2006). Post-coital antifertility activity of Achyranthes aspera Linn. root. Journal of Ethnopharmacology, 107(2), 179–181.

[38]. Vetrichelvan, T., & Jegadeesan, M. (2003). Effect of alcohol extract of Achyranthes aspera Linn. on acute and subacute inflammation. Phytotherapy Research, 17(1), 77–79. https://doi.org/10.1002/ptr.1070

[39]. Jiang, Y., Li, W., Wang, Z., & Lu, J. (2024). Lipid-based nanotechnology: Liposome. Pharmaceutics, 16, 34. https://doi.org/10.3390/pharmaceutics16010034

[40]. Lakkis, J. M. (2007). Encapsulation and controlled release technologies in food systems. Blackwell Publishing.

[41]. Laridi, R., Kheadr, E. E., Benech, R., et al. (2003). Liposome encapsulated nisin Z: Optimization, stability and release during milk fermentation. International Dairy Journal, 13, 325–336. https://doi.org/10.1016/S0958-6946(02)00194-2

[42]. Peng, T., Xu, W., Li, Q., Ding, Y., & Huang, Y. (2022). Pharmaceutical liposomal delivery—Specific considerations of innovation and challenges. Biomaterials Science, 11, 62–75. https://doi.org/10.1039/d2bm01252a

[43]. Rudzińska, M., Grygier, A., Knight, G., & Kmiecik, D. (2024). Liposomes as carriers of bioactive compounds in human nutrition. Foods, 13(12), 1814. https://doi.org/10.3390/foods13121814

[44]. Sharma, A., & Sharma, U. S. (1997). Liposomes in drug delivery: Progress and limitations. International Journal of Pharmaceutics, 154(2), 123–140. https://doi.org/10.1016/S0378-5173(97)00135-X

[45]. Shukla, S., Haldorai, Y., Hwang, S. K., et al. (2017). Current demands for food-approved liposome nanoparticles in food and safety sector. Frontiers in Microbiology, 8, 2398. https://doi.org/10.3389/fmicb.2017.02398

[46]. Storm, G., & Crommelin, D. J. A. (1998). Liposomes: Quo vadis? Pharmaceutical Science & Technology Today, 1, 19–31. https://doi.org/10.1016/S1461-5347(98)00007-8

[47]. Subramani, T., & Ganapathyswamy, H. (2020). An overview of liposomal nano-encapsulation techniques and its applications in food and nutraceutical. Journal of Food Science and Technology, 57(10), 3545–3555. https://doi.org/10.1007/s13197-020-04360-2

[48]. Trucillo, P., Campardelli, R., Iuorio, S., De Stefanis, P., &Reverchon, E. (2020). Economic analysis of a new business for liposome manufacturing using a high-pressure system. Processes, 8, 1604. https://doi.org/10.3390/pr8121604

[49]. Xu, X., Tian, M., Deng, L., Jiang, H., Han, J., Zhen, C., Huang, L., & Liu, W. (2023). Structural degradation and uptake of resveratrol-encapsulated liposomes using an in vitro digestion combined with Caco-2 cell absorption model. Food Chemistry, 403, 133943. https://doi.org/10.1016/j.foodchem.2022.133943